Current Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and Treatment

Neoplasia (United States)

Volumn 18, Issue 11, 2016, Pages 674-688

  Kotta Loizou, Ioly ^a,b   Vasilopoulos, Spyridon N ^b   Coutts, Robert H A ^c   Theocharis, Stamatios ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ELAV LIKE PROTEIN 1; FLUOROURACIL; LAPATINIB; MESSENGER RNA; MICRORNA; TAMOXIFEN; ANTINEOPLASTIC AGENT; PROTEIN BINDING;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; CELL ADHESION; CELL CYCLE; CLINICAL STUDY; DRUG EFFECT; DRUG TARGETING; GENETIC TRANSCRIPTION; HUMAN; IN VIVO STUDY; INFLAMMATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BREAST NEOPLASMS; CANCER GRADING; CELL TRANSFORMATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; PROGNOSIS; PROTEIN TRANSPORT; RADIATION RESPONSE; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; ELAV-LIKE PROTEIN 1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM GRADING; PHOSPHORYLATION; PROGNOSIS; PROTEIN BINDING; PROTEIN TRANSPORT; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 85016022999     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2016.09.002     Document Type: Review

References (123)

1. [1] Ma, W.J., Cheng, S., Campbell, C., Wright, A., Furneaux, H., Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J Biol Chem 271 (1996), 8144–8151.
2. [2] Burd, C.G., Dreyfuss, G., Conserved structures and diversity of functions of RNA-binding proteins. Science 265 (1994), 615–621.
3. [3] Levine, T.D., Gao, F., King, P.H., Andrews, L.G., Keene, J.D., Hel-N1: an autoimmune RNA-binding protein with specificity for 3’ uridylate-rich untranslated regions of growth factor mRNAs. Mol Cell Biol 13 (1993), 3494–3504.
4. [4] Lopez de Silanes, I., Zhan, M., Lal, A., Yang, X., Gorospe, M., Identification of a target RNA motif for RNA-binding protein HuR. Proc Natl Acad Sci U S A 101 (2004), 2987–2992.
5. [5] Brennan, C.M., Steitz, J.A., HuR and mRNA stability. Cell Mol Life Sci 58 (2001), 266–277.
6. [6] Myer, V.E., Fan, X.C., Steitz, J.A., Identification of HuR as a protein implicated in AUUUA-mediated mRNA decay. EMBO J 16 (1997), 2130–2139.
7. [7] Fan, X.C., Steitz, J.A., Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J 17 (1998), 3448–3460.
8. [8] Peng, S.S., Chen, C.Y., Xu, N., Shyu, A.B., RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. EMBO J 17 (1998), 3461–3470.
9. [9] Kullmann, M., Gopfert, U., Siewe, B., Hengst, L., ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5'UTR. Genes Dev 16 (2002), 3087–3099.
10. [10] Mazan-Mamczarz, K., Galban, S., Lopez de Silanes, I., Martindale, J.L., Atasoy, U., Keene, J.D., Gorospe, M., RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci U S A 100 (2003), 8354–8359.
11. [11] Zhu, H., Zhou, H.L., Hasman, R.A., Lou, H., Hu proteins regulate polyadenylation by blocking sites containing U-rich sequences. J Biol Chem 282 (2007), 2203–2210.
12. [12] Izquierdo, J.M., Hu antigen R (HuR) functions as an alternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition. J Biol Chem 283 (2008), 19077–19084.
13. [13] Mukherjee, N., Corcoran, D.L., Nusbaum, J.D., Reid, D.W., Georgiev, S., Hafner, M., Ascano, M. Jr., Tuschl, T., Ohler, U., Keene, J.D., Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. Mol Cell 43 (2011), 327–339.
14. [14] Akaike, Y., Masuda, K., Kuwano, Y., Nishida, K., Kajita, K., Kurokawa, K., Satake, Y., Shoda, K., Imoto, I., Rokutan, K., HuR regulates alternative splicing of the TRA2beta gene in human colon cancer cells under oxidative stress. Mol Cell Biol 34 (2014), 2857–2873.
15. [15] Fan, X.C., Steitz, J.A., HNS, a nuclear-cytoplasmic shuttling sequence in HuR. Proc Natl Acad Sci U S A 95 (1998), 15293–15298.
16. [16] Keene, J.D., Why is Hu where? Shuttling of early-response-gene messenger RNA subsets. Proc Natl Acad Sci U S A 96 (1999), 5–7.
17. [17] Li, H., Park, S., Kilburn, B., Jelinek, M.A., Henschen-Edman, A., Aswad, D.W., Stallcup, M.R., Laird-Offringa, I.A., Lipopolysaccharide-induced methylation of HuR, an mRNA-stabilizing protein, by CARM1. Coactivator-associated arginine methyltransferase. J Biol Chem 277 (2002), 44623–44630.
18. [18] Abdelmohsen, K., Srikantan, S., Kuwano, Y., Gorospe, M., miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. Proc Natl Acad Sci U S A 105 (2008), 20297–20302.
19. [19] Cabilla, J.P., Nudler, S.I., Ronchetti, S.A., Quinteros, F.A., Lasaga, M., Duvilanski, B.H., Nitric oxide-sensitive guanylyl cyclase is differentially regulated by nuclear and non-nuclear estrogen pathways in anterior pituitary gland. PLoS One, 6, 2011, e29402.
20. [20] Akool, E.-S., Kleinert, H., Hamada, F.M., Abdelwahab, M.H., Forstermann, U., Pfeilschifter, J., Eberhardt, W., Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol Cell Biol 23 (2003), 4901–4916.
21. [21] Abdelmohsen, K., Srikantan, S., Yang, X., Lal, A., Kim, H.H., Kuwano, Y., Galban, S., Becker, K.G., Kamara, D., de Cabo, R., et al. Ubiquitin-mediated proteolysis of HuR by heat shock. EMBO J 28 (2009), 1271–1282.
22. [22] Mazroui, R., Di Marco, S., Clair, E., von Roretz, C., Tenenbaum, S.A., Keene, J.D., Saleh, M., Gallouzi, I.E., Caspase-mediated cleavage of HuR in the cytoplasm contributes to pp32/PHAP-I regulation of apoptosis. J Cell Biol 180 (2008), 113–127.
23. [23] Yiakouvaki, A., Dimitriou, M., Karakasiliotis, I., Eftychi, C., Theocharis, S., Kontoyiannis, D.L., Myeloid cell expression of the RNA-binding protein HuR protects mice from pathologic inflammation and colorectal carcinogenesis. J Clin Invest 122 (2012), 48–61.
24. [24] Rhee, W.J., Ni, C.W., Zheng, Z., Chang, K., Jo, H., Bao, G., HuR regulates the expression of stress-sensitive genes and mediates inflammatory response in human umbilical vein endothelial cells. Proc Natl Acad Sci U S A 107 (2010), 6858–6863.
25. [25] Zhang, J., Modi, Y., Yarovinsky, T., Yu, J., Collinge, M., Kyriakides, T., Zhu, Y., Sessa, W.C., Pardi, R., Bender, J.R., Macrophage beta2 integrin-mediated, HuR-dependent stabilization of angiogenic factor-encoding mRNAs in inflammatory angiogenesis. Am J Pathol 180 (2012), 1751–1760.
26. [26] Lopez de Silanes, I., Lal, A., Gorospe, M., HuR: post-transcriptional paths to malignancy. RNA Biol 2 (2005), 11–13.
27. [27] Wang, J., Zhao, W., Guo, Y., Zhang, B., Xie, Q., Xiang, D., Gao, J., Wang, B., Chen, Z., The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis. Oncology 76 (2009), 420–429.
28. [28] Kurosu, T., Ohga, N., Hida, Y., Maishi, N., Akiyama, K., Kakuguchi, W., Kuroshima, T., Kondo, M., Akino, T., Totsuka, Y., et al. HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. Br J Cancer 104 (2011), 819–829.
29. [29] Lopez de Silanes, I., Fan, J., Yang, X., Zonderman, A.B., Potapova, O., Pizer, E.S., Gorospe, M., Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene 22 (2003), 7146–7154.
30. [30] Abdelmohsen, K., Lal, A., Kim, H.H., Gorospe, M., Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle 6 (2007), 1288–1292.
31. [31] Katsanou, V., Papadaki, O., Milatos, S., Blackshear, P.J., Anderson, P., Kollias, G., Kontoyiannis, D.L., HuR as a negative posttranscriptional modulator in inflammation. Mol Cell 19 (2005), 777–789.
32. [32] Sengupta, S., Jang, B.C., Wu, M.T., Paik, J.H., Furneaux, H., Hla, T., The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem 278 (2003), 25227–25233.
33. [33] Wang, W., Caldwell, M.C., Lin, S., Furneaux, H., Gorospe, M., HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J 19 (2000), 2340–2350.
34. [34] Kotta-Loizou, I., Giaginis, C., Theocharis, S., Clinical significance of HuR expression in human malignancy. Med Oncol, 31, 2014, 161.
35. [35] Skibinski, A., Kuperwasser, C., The origin of breast tumor heterogeneity. Oncogene, 2015.
36. [36] Wang, L., Gallo, K.A., Conrad, S.E., Targeting mixed lineage kinases in ER-positive breast cancer cells leads to G2/M cell cycle arrest and apoptosis. Oncotarget 4 (2013), 1158–1171.
37. [37] Hostetter, C., Licata, L.A., Witkiewicz, A., Costantino, C.L., Yeo, C.J., Brody, J.R., Keen, J.C., Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther 7 (2008), 1496–1506.
38. [38] Scott, G.K., Marx, C., Berger, C.E., Saunders, L.R., Verdin, E., Schafer, S., Jung, M., Benz, C.C., Destabilization of ERBB2 transcripts by targeting 3’ untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res 6 (2008), 1250–1258.
39. [39] Abdelmohsen, K., Pullmann, R. Jr., Lal, A., Kim, H.H., Galban, S., Yang, X., Blethrow, J.D., Walker, M., Shubert, J., Gillespie, D.A., et al. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell 25 (2007), 543–557.
40. [40] Yu, T.X., Wang, P.Y., Rao, J.N., Zou, T., Liu, L., Xiao, L., Gorospe, M., Wang, J.Y., Chk2-dependent HuR phosphorylation regulates occludin mRNA translation and epithelial barrier function. Nucleic Acids Res 39 (2011), 8472–8487.
41. [41] Lafarga, V., Cuadrado, A., Lopez de Silanes, I., Bengoechea, R., Fernandez-Capetillo, O., Nebreda, A.R., p38 Mitogen-activated protein kinase- and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint. Mol Cell Biol 29 (2009), 4341–4351.
42. [42] Schulz, S., Doller, A., Pendini, N.R., Wilce, J.A., Pfeilschifter, J., Eberhardt, W., Domain-specific phosphomimetic mutation allows dissection of different protein kinase C (PKC) isotype-triggered activities of the RNA binding protein HuR. Cell Signal 25 (2013), 2485–2495.
43. [43] Doller, A., Huwiler, A., Muller, R., Radeke, H.H., Pfeilschifter, J., Eberhardt, W., Protein kinase C alpha-dependent phosphorylation of the mRNA-stabilizing factor HuR: implications for posttranscriptional regulation of cyclooxygenase-2. Mol Biol Cell 18 (2007), 2137–2148.
44. [44] Yoon, J.H., Abdelmohsen, K., Srikantan, S., Guo, R., Yang, X., Martindale, J.L., Gorospe, M., Tyrosine phosphorylation of HuR by JAK3 triggers dissociation and degradation of HuR target mRNAs. Nucleic Acids Res 42 (2014), 1196–1208.
45. [45] Kim, H.H., Abdelmohsen, K., Lal, A., Pullmann, R. Jr., Yang, X., Galban, S., Srikantan, S., Martindale, J.L., Blethrow, J., Shokat, K.M., et al. Nuclear HuR accumulation through phosphorylation by Cdk1. Genes Dev 22 (2008), 1804–1815.
46. [46] Doller, A., Schlepckow, K., Schwalbe, H., Pfeilschifter, J., Eberhardt, W., Tandem phosphorylation of serines 221 and 318 by protein kinase Cdelta coordinates mRNA binding and nucleocytoplasmic shuttling of HuR. Mol Cell Biol 30 (2010), 1397–1410.
47. [47] Doller, A., Akool el, S., Huwiler, A., Muller, R., Radeke, H.H., Pfeilschifter, J., Eberhardt, W., Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA. Mol Cell Biol 28 (2008), 2608–2625.
48. [48] Doller, A., Winkler, C., Azrilian, I., Schulz, S., Hartmann, S., Pfeilschifter, J., Eberhardt, W., High-constitutive HuR phosphorylation at Ser 318 by PKC{delta} propagates tumor relevant functions in colon carcinoma cells. Carcinogenesis 32 (2011), 676–685.
49. [49] Al-Ahmadi, W., Al-Ghamdi, M., Al-Souhibani, N., Khabar, K.S., miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer. J Pathol 230 (2013), 28–38.
50. [50] Leandersson, K., Riesbeck, K., Andersson, T., Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells. Nucleic Acids Res 34 (2006), 3988–3999.
51. [51] Woo, H.H., Zhou, Y., Yi, X., David, C.L., Zheng, W., Gilmore-Hebert, M., Kluger, H.M., Ulukus, E.C., Baker, T., Stoffer, J.B., et al. Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer. Oncogene 28 (2009), 1176–1186.
52. [52] Calaluce, R., Gubin, M.M., Davis, J.W., Magee, J.D., Chen, J., Kuwano, Y., Gorospe, M., Atasoy, U., The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer. BMC Cancer, 10, 2010, 126.
53. [53] Guo, X., Hartley, R.S., HuR contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. Cancer Res 66 (2006), 7948–7956.
54. [54] Guo, X., Wu, Y., Hartley, R.S., MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol 6 (2009), 575–583.
55. [55] Meng, Z., Jackson, N.L., Choi, H., King, P.H., Emanuel, P.D., Blume, S.W., Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF-IR translational control in human breast tumor cells. J Cell Physiol 217 (2008), 172–183.
56. [56] Saunus, J.M., French, J.D., Edwards, S.L., Beveridge, D.J., Hatchell, E.C., Wagner, S.A., Stein, S.R., Davidson, A., Simpson, K.J., Francis, G.D., et al. Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR. Cancer Res 68 (2008), 9469–9478.
57. [57] Yuan, Z., Sanders, A.J., Ye, L., Wang, Y., Jiang, W.G., Prognostic value of the human antigen R (HuR) in human breast cancer: high level predicts a favourable prognosis. Anticancer Res 31 (2011), 303–310.
58. [58] Suswam, E.A., Nabors, L.B., Huang, Y., Yang, X., King, P.H., IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3’ untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR. Int J Cancer 113 (2005), 911–919.
59. [59] Gabai, V.L., Meng, L., Kim, G., Mills, T.A., Benjamin, I.J., Sherman, M.Y., Heat shock transcription factor Hsf1 is involved in tumor progression via regulation of hypoxia-inducible factor 1 and RNA-binding protein HuR. Mol Cell Biol 32 (2012), 929–940.
60. [60] Chock, K., Allison, J.M., Elshamy, W.M., BRCA1-IRIS overexpression abrogates UV-induced p38MAPK/p53 and promotes proliferation of damaged cells. Oncogene 29 (2010), 5274–5285.
61. [61] Latorre, E., Castiglioni, I., Gatto, P., Carelli, S., Quattrone, A., Provenzani, A., Loss of protein kinase Cdelta/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines. J Pharmacol Exp Ther 349 (2014), 99–106.
62. [62] Ortega, A.D., Sala, S., Espinosa, E., Gonzalez-Baron, M., Cuezva, J.M., HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence. Carcinogenesis 29 (2008), 2053–2061.
63. [63] Xu, F., Zhang, X., Lei, Y., Liu, X., Liu, Z., Tong, T., Wang, W., Loss of repression of HuR translation by miR-16 may be responsible for the elevation of HuR in human breast carcinoma. J Cell Biochem 111 (2010), 727–734.
64. [64] Heinonen, M., Hemmes, A., Salmenkivi, K., Abdelmohsen, K., Vilen, S.T., Laakso, M., Leidenius, M., Salo, T., Hautaniemi, S., Gorospe, M., et al. Role of RNA binding protein HuR in ductal carcinoma in situ of the breast. J Pathol 224 (2011), 529–539.
65. [65] Zhu, Z., Wang, B., Bi, J., Zhang, C., Guo, Y., Chu, H., Liang, X., Zhong, C., Wang, J., Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer. Tumour Biol 34 (2013), 2299–2308.
66. [66] Denkert, C., Weichert, W., Winzer, K.J., Muller, B.M., Noske, A., Niesporek, S., Kristiansen, G., Guski, H., Dietel, M., Hauptmann, S., Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res 10 (2004), 5580–5586.
67. [67] Heinonen, M., Bono, P., Narko, K., Chang, S.H., Lundin, J., Joensuu, H., Furneaux, H., Hla, T., Haglund, C., Ristimaki, A., Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 65 (2005), 2157–2161.
68. [68] Wang, J., Li, D., Wang, B., Wu, Y., Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 141 (2013), 213–224.
69. [69] Yan, W., Zhang, Y., Zhang, J., Cho, S.J., Chen, X., HuR is necessary for mammary epithelial cell proliferation and polarity at least in part via DeltaNp63. PLoS One, 7, 2012, e45336.
70. [70] Mazan-Mamczarz, K., Hagner, P.R., Dai, B., Wood, W.H., Zhang, Y., Becker, K.G., Liu, Z., Gartenhaus, R.B., Identification of transformation-related pathways in a breast epithelial cell model using a ribonomics approach. Cancer Res 68 (2008), 7730–7735.
71. [71] Licata, L.A., Hostetter, C.L., Crismale, J., Sheth, A., Keen, J.C., The RNA-binding protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines. Breast Cancer Res Treat 122 (2010), 55–63.
72. [72] Gubin, M.M., Calaluce, R., Davis, J.W., Magee, J.D., Strouse, C.S., Shaw, D.P., Ma, L., Brown, A., Hoffman, T., Rold, T.L., et al. Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis. Cell Cycle 9 (2010), 3337–3346.
73. [73] Woo, H.H., Yi, X., Lamb, T., Menzl, I., Baker, T., Shapiro, D.J., Chambers, S.K., Posttranscriptional suppression of proto-oncogene c-fms expression by vigilin in breast cancer. Mol Cell Biol 31 (2011), 215–225.
74. [74] Tenenbaum, S.A., Carson, C.C., Lager, P.J., Keene, J.D., Identifying mRNA subsets in messenger ribonucleoprotein complexes by using cDNA arrays. Proc Natl Acad Sci U S A 97 (2000), 14085–14090.
75. [75] Mazan-Mamczarz, K., Hagner, P.R., Corl, S., Srikantan, S., Wood, W.H., Becker, K.G., Gorospe, M., Keene, J.D., Levenson, A.S., Gartenhaus, R.B., Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. Oncogene 27 (2008), 6151–6163.
76. [76] Pryzbylkowski, P., Obajimi, O., Keen, J.C., Trichostatin A and 5 Aza-2’ deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. Breast Cancer Res Treat 111 (2008), 15–25.
77. [77] Li, Y., Yu, J., Du, D., Fu, S., Chen, Y., Yu, F., Gao, P., Involvement of post-transcriptional regulation of FOXO1 by HuR in 5-FU-induced apoptosis in breast cancer cells. Oncol Lett 6 (2013), 156–160.
78. [78] Yang, F., Miao, L., Mei, Y., Wu, M., Retinoic acid-induced HOXA5 expression is co-regulated by HuR and miR-130a. Cell Signal 25 (2013), 1476–1485.
79. [79] Latorre, E., Tebaldi, T., Viero, G., Sparta, A.M., Quattrone, A., Provenzani, A., Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells. Mol Cancer, 11, 2012, 13.
80. [80] Sommer, S., Cui, Y., Brewer, G., Fuqua, S.A., The c-Yes 3'-UTR contains adenine/uridine-rich elements that bind AUF1 and HuR involved in mRNA decay in breast cancer cells. J Steroid Biochem Mol Biol 97 (2005), 219–229.
81. [81] Al-Souhibani, N., Al-Ghamdi, M., Al-Ahmadi, W., Khabar, K.S., Posttranscriptional control of the chemokine receptor CXCR4 expression in cancer cells. Carcinogenesis 35 (2014), 1983–1992.
82. [82] Giles, K.M., Daly, J.M., Beveridge, D.J., Thomson, A.M., Voon, D.C., Furneaux, H.M., Jazayeri, J.A., Leedman, P.J., The 3'-untranslated region of p21WAF1 mRNA is a composite cis-acting sequence bound by RNA-binding proteins from breast cancer cells, including HuR and poly(C)-binding protein. J Biol Chem 278 (2003), 2937–2946.
83. [83] Hsia, T.C., Tu, C.Y., Chen, Y.J., Wei, Y.L., Yu, M.C., Hsu, S.C., Tsai, S.L., Chen, W.S., Yeh, M.H., Yen, C.J., et al. Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells. Mol Pharmacol 83 (2013), 857–869.
84. [84] Luo, N.A., Qu, Y.Q., Yang, G.D., Wang, T., Li, R.L., Jia, L.T., Dong, R., Post-transcriptional up-regulation of PDGF-C by HuR in advanced and stressed breast cancer. Int J Mol Sci 15 (2014), 20306–20320.
85. [85] Hewitt, S.C., Harrell, J.C., Korach, K.S., Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol 67 (2005), 285–308.
86. [86] Hoch, R.V., Thompson, D.A., Baker, R.J., Weigel, R.J., GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 84 (1999), 122–128.
87. [87] Rhoads, K., Arderiu, G., Charboneau, A., Hansen, S.L., Hoffman, W., Boudreau, N., A role for Hox A5 in regulating angiogenesis and vascular patterning. Lymphat Res Biol 3 (2005), 240–252.
88. [88] Leris, A.C., Roberts, T.R., Jiang, W.G., Newbold, R.F., Mokbel, K., WNT5A expression in human breast cancer. Anticancer Res 25 (2005), 731–734.
89. [89] Gallo, D., Jacquot, Y., Laurent, G., Leclercq, G., Calmodulin, a regulatory partner of the estrogen receptor alpha in breast cancer cells. Mol Cell Endocrinol 291 (2008), 20–26.
90. [90] Rzymski, T., Paantjens, A., Bod, J., Harris, A.L., Multiple pathways are involved in the anoxia response of SKIP3 including HuR-regulated RNA stability, NF-kappaB and ATF4. Oncogene 27 (2008), 4532–4543.
91. [91] Wang, W., Furneaux, H., Cheng, H., Caldwell, M.C., Hutter, D., Liu, Y., Holbrook, N., Gorospe, M., HuR regulates p21 mRNA stabilization by UV light. Mol Cell Biol 20 (2000), 760–769.
92. [92] Guo, X., Wu, Y., Hartley, R.S., Cold-inducible RNA-binding protein contributes to human antigen R and cyclin E1 deregulation in breast cancer. Mol Carcinog 49 (2010), 130–140.
93. [93] Guo, X., Connick, M.C., Vanderhoof, J., Ishak, M.A., Hartley, R.S., MicroRNA-16 modulates HuR regulation of cyclin E1 in breast cancer cells. Int J Mol Sci 16 (2015), 7112–7132.
94. [94] Heinonen, M., Fagerholm, R., Aaltonen, K., Kilpivaara, O., Aittomaki, K., Blomqvist, C., Heikkila, P., Haglund, C., Nevanlinna, H., Ristimaki, A., Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res 13 (2007), 6959–6963.
95. [95] Todorovic-Rakovic, N., Milovanovic, J., Interleukin-8 in breast cancer progression. J Interferon Cytokine Res 33 (2013), 563–570.
96. [96] Koch, A.E., Polverini, P.J., Kunkel, S.L., Harlow, L.A., DiPietro, L.A., Elner, V.M., Elner, S.G., Strieter, R.M., Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258 (1992), 1798–1801.
97. [97] Swierczak, A., Cook, A.D., Lenzo, J.C., Restall, C.M., Doherty, J.P., Anderson, R.L., Hamilton, J.A., The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor. Cancer Immunol Res 2 (2014), 765–776.
98. [98] Ioachim, E., Damala, K., Tsanou, E., Briasoulis, E., Papadiotis, E., Mitselou, A., Charhanti, A., Doukas, M., Lampri, L., Arvanitis, D.L., Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. Histol Histopathol 27 (2012), 209–216.
99. [99] Suh, E.J., Kabir, M.H., Kang, U.B., Lee, J.W., Yu, J., Noh, D.Y., Lee, C., Comparative profiling of plasma proteome from breast cancer patients reveals thrombospondin-1 and BRWD3 as serological biomarkers. Exp Mol Med 44 (2012), 36–44.
100. [100] Mehner, C., Hockla, A., Miller, E., Ran, S., Radisky, D.C., Radisky, E.S., Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget 5 (2014), 2736–2749.
101. [101] Wang, W., He, Y.F., Sun, Q.K., Wang, Y., Han, X.H., Peng, D.F., Yao, Y.W., Ji, C.S., Hu, B., Hypoxia-inducible factor 1alpha in breast cancer prognosis. Clin Chim Acta 428 (2014), 32–37.
102. [102] Hostetter, C.L., Licata, L.A., Keen, J.C., Timing is everything: order of administration of 5-aza 2’ deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity. Cancer Lett 275 (2009), 178–184.
103. [103] Shimizu, Y., Luk, H., Horio, D., Miron, P., Griswold, M., Iglehart, D., Hernandez, B., Killeen, J., ElShamy, W.M., BRCA1-IRIS overexpression promotes formation of aggressive breast cancers. PLoS One, 7, 2012, e34102.
104. [104] Kang, M.J., Ryu, B.K., Lee, M.G., Han, J., Lee, J.H., Ha, T.K., Byun, D.S., Chae, K.S., Lee, B.H., Chun, H.S., et al. NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. Gastroenterology 135:2030-2042 (2008), 2042.e2031–2042.e2033.
105. [105] Artero-Castro, A., Callejas, F.B., Castellvi, J., Kondoh, H., Carnero, A., Fernandez-Marcos, P.J., Serrano, M., Ramon y Cajal, S., Lleonart, M.E., Cold-inducible RNA-binding protein bypasses replicative senescence in primary cells through extracellular signal-regulated kinase 1 and 2 activation. Mol Cell Biol 29 (2009), 1855–1868.
106. [106] Dai, C., Whitesell, L., Rogers, A.B., Lindquist, S., Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130 (2007), 1005–1018.
107. [107] Alao, J.P., Lam, E.W., Ali, S., Buluwela, L., Bordogna, W., Lockey, P., Varshochi, R., Stavropoulou, A.V., Coombes, R.C., Vigushin, D.M., Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 10 (2004), 8094–8104.
108. [108] Finn, R.S., Press, M.F., Dering, J., Arbushites, M., Koehler, M., Oliva, C., Williams, L.S., Di Leo, A., Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol 27 (2009), 3908–3915.
109. [109] Tran, H., Maurer, F., Nagamine, Y., Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol Cell Biol 23 (2003), 7177–7188.
110. [110] Sheflin, L.G., Zou, A.P., Spaulding, S.W., Androgens regulate the binding of endogenous HuR to the AU-rich 3'UTRs of HIF-1alpha and EGF mRNA. Biochem Biophys Res Commun 322 (2004), 644–651.
111. [111] Danilin, S., Sourbier, C., Thomas, L., Lindner, V., Rothhut, S., Dormoy, V., Helwig, J.J., Jacqmin, D., Lang, H., Massfelder, T., Role of the RNA-binding protein HuR in human renal cell carcinoma. Carcinogenesis 31 (2010), 1018–1026.
112. [112] Levy, N.S., Chung, S., Furneaux, H., Levy, A.P., Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 273 (1998), 6417–6423.
113. [113] Arnold, A., Papanikolaou, A., Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23 (2005), 4215–4224.
114. [114] Kang, J., Sergio, C.M., Sutherland, R.L., Musgrove, E.A., Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer, 14, 2014, 32.
115. [115] Wang, Y., Liu, F., Mao, F., Hang, Q., Huang, X., He, S., Cheng, C., Wang, H., Xu, G., Zhang, T., et al. Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration. J Biol Chem 288 (2013), 9028–9034.
116. [116] Nannuru, K.C., Futakuchi, M., Varney, M.L., Vincent, T.M., Marcusson, E.G., Singh, R.K., Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. Cancer Res 70 (2010), 3494–3504.
117. [117] Bilal, E., Alexe, G., Yao, M., Cong, L., Kulkarni, A., Ginjala, V., Toppmeyer, D., Ganesan, S., Bhanot, G., Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers. Genes Cancer 1 (2010), 1063–1073.
118. [118] Meisner, N.C., Hintersteiner, M., Mueller, K., Bauer, R., Seifert, J.M., Naegeli, H.U., Ottl, J., Oberer, L., Guenat, C., Moss, S., et al. Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR. Nat Chem Biol 3 (2007), 508–515.
119. [119] Wu, X., Lan, L., Wilson, D.M., Marquez, R.T., Tsao, W.C., Gao, P., Roy, A., Turner, B.A., McDonald, P., Tunge, J.A., et al. Identification and validation of novel small molecule disruptors of HuR-mRNA interaction. ACS Chem Biol 10 (2015), 1476–1484.
120. [120] Wang, Z., Bhattacharya, A., Ivanov, D.N., Identification of Small-Molecule Inhibitors of the HuR/RNA Interaction Using a Fluorescence Polarization Screening Assay Followed by NMR Validation. PLoS One, 10, 2015, e0138780.
121. [121] D'Agostino, V.G., Adami, V., Provenzani, A., A novel high throughput biochemical assay to evaluate the HuR protein-RNA complex formation. PLoS One, 8, 2013, e72426.
122. [122] Chae, M.J., Sung, H.Y., Kim, E.H., Lee, M., Kwak, H., Chae, C.H., Kim, S., Park, W.Y., Chemical inhibitors destabilize HuR binding to the AU-rich element of TNF-alpha mRNA. Exp Mol Med 41 (2009), 824–831.
123. [123] D'Agostino, V.G., Lal, P., Mantelli, B., Tiedje, C., Zucal, C., Thongon, N., Gaestel, M., Latorre, E., Marinelli, L., Seneci, P., et al. Dihydrotanshinone-I interferes with the RNA-binding activity of HuR affecting its post-transcriptional function. Sci Rep, 5, 2015, 16478.